Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Agilent unveils three new microRNA microarray designs

Agilent Technologies Europe : 11 April, 2008  (New Product)
Three new microRNA microarray designs (Human miRNA Microarray v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0) have been introduced by Agilent Technologies.
All the designs are based on the Sanger Institute's miRBase 10.1 which was updated in December 2007.

'Researchers tell us that they value specificity and sensitivity above other attributes, and this plays well to Agilent's strengths in Microarray manufacturing,' said Yvonne Linney, Agilent vice president and general manager, Genomics. 'Our breakthrough direct-labelling method requires very small amounts of sample input, and the flexibility of our SurePrint inkjet fabrication platform makes it extremely easy to update content as it becomes available.'

The updated Human miRNA Microarray v2.0 contains 723 human and 76 human viral probe sets. Viral miRNAs are increasingly associated with some cancers, so Agilent included these probe sets to provide additional value for cancer researchers.

The new Mouse miRNA Microarray v1.0 contains all known mouse and mouse gamma herpes virus miRNAs. There are 567 mouse and 10 mouse gamma herpes virus distinct probe sets.

The new Rat miRNA Microarray v1.0 contains all 350 known rat miRNA probe sets.

Agilent launched the first comprehensive Microarray system for expression profiling of human miRNAs in April 2007.

'Tumour-specific predictors based on high-throughput nucleic acid assays offer significant advances over current clinically -derived models,' said David Neil Hayes, MD, assistant professor of medicine, Division of Hematology/Oncology, University of North Carolina School of Medicine. The Hayes team is studying glioblastoma, a highly aggressive type of brain tumour. 'My team is on the cusp of being able to correlate a tumour's genetic pattern to clinically-relevant events. We would be hard-pressed to reach this ability in such a short period of time to elucidate a tumour's genetic pattern and understand the regulatory networks between miRNA and gene expression, without the use of Agilent's miRNA and gene expression arrays.'

The Agilent miRNA Microarray platform's limit of detection is less than 1 attomole with a dynamic range of five orders of magnitude. Probe specificity and the unique labeling procedure discriminates individual miRNAs. Agilent's novel method for efficiently labelling miRNA in total RNA eliminates tedious size fractionation and requires only 100 nanograms of input RNA from precious samples.

The Agilent miRNA assays are delivered as eight 15K arrays per standard 1 x 3inch glass slide. The Human v2.0 kit, Mouse v1.0 kit and Rat v1.0 kit are each available as two different pack sizes: one slide with eight arrays or three slides with 24 arrays. The human, mouse and rat miRNA assays are also available as individual slides, each containing eight microarrays. This helps users tailor purchases to their research requirements.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo